Marie‐Louise Lehmann

Polymorphic Enzymes, Urinary Bladder Cancer Risk, and Structural Change in the Local Industry

Silvia Selinski, Marie‐Louise Lehmann, Meinolf Blaszkewicz et al. · Journal of Toxicology and Environmental Health · 2012 · 55 citations

Urological Research, Urology, Polymorphic Enzymes +12

Perpetrator effects of ciclosporin (P‐glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers

Antonia Brings, Marie‐Louise Lehmann, Kathrin I. Foerster et al. · British Journal of Clinical Pharmacology · 2019 · 35 citations · Full text

<i>CHL1</i> , <i>ITGB3</i> and <i>SLC6A4</i> Gene Expression and Antidepressant Drug Response: Results from the Munich Antidepressant Response Signature (MARS) Study

Kristina Probst-Schendzielorz, Catharina Scholl, Olga Efimkina et al. · Pharmacogenomics · 2015 · 21 citations

Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug–drug interactions with different perpetrator drugs

Gerd Mikus, Kathrin I. Foerster, Marlene Schaumaeker et al. · British Journal of Clinical Pharmacology · 2020 · 19 citations · Full text

Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene

Silvia Selinski, Marie‐Louise Lehmann, Meinolf Blaszkewicz et al. · Archives of Toxicology · 2011 · 17 citations

Urological Research, Urology, Urologic Cancer Epidemiology +6